MedPath

Prospective Clinical Assessment Study in Children with Hypochondroplasia

Recruiting
Conditions
Hypochondroplasia
Registration Number
NCT06410976
Lead Sponsor
QED Therapeutics, Inc.
Brief Summary

This is a long-term, multicenter, non-interventional study of children ages 2.5 to \<17 years with hypochondroplasia (HCH).

Detailed Description

The objective is to evaluate growth, HCH-related medical complications, health-related quality of life, functional abilities and cognitive functions of study participants. Data collected will contribute to the characterization of the natural history of children with HCH. No study medication will be administered.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
150
Inclusion Criteria

Signed informed consent.

Aged 2.5 to <17 years at study entry.

Diagnosis of HCH documented clinically by the presence of disproportionate short stature and confirmed with a molecular test.

Participants are ambulatory and able to stand without assistance.

Study participants and parent(s), guardian(s), or caregiver(s) are willing and able to comply with study visits and study procedures.

Exclusion Criteria

Have ACH or short stature condition other than HCH.

In females, having had their menarche. Annualized height growth velocity ≤1.5 cm/year over a period ≥6 months prior to screening.

Having a clinically significant disease or condition that in view of the investigator or Sponsor will interfere with the evaluation of growth, with study participation or not be in the best interest of the participant.

Clinically significant abnormality in any laboratory test result at screening

Have been treated with growth hormone, IGF 1, or anabolic steroids the previous 6 months or long-term treatment (>3 months) at any time.

Current evidence of corneal or retinal disorders.

Have used any other investigational product or investigational medical device for the treatment of HCH or short stature.

Have had regular long-term treatment (>1 month) with oral corticosteroids (low-dose ongoing inhaled steroid for asthma is acceptable).

Previous limb-lengthening surgery or guided growth surgery with plates still in place or removed within the 6 months prior to screening.

Having had a fracture of the long bones or spine within 12 months of screening.

History and/or current evidence of extensive ectopic tissue calcification.

History of malignancy.

Concurrent circumstance, disease, or condition that, in the view of the investigator and/or sponsor, would interfere with study participation, and/or would place the participant at high risk for poor compliance with study activities or for not completing the study.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Annualized height velocityup to 2 years
Secondary Outcome Measures
NameTimeMethod
Cognitive functionsup to 2 years
Change over time in height Z-score, upper arm to forearm ratio, and upper leg to lower leg ratioup to 2 years
HCH-related medical events reported as medical history or NT-AEsup to 2 years
HCH-related surgical proceduresup to 2 years
Change from BL in the Physical Functioning dimension of the Pediatric Quality of Life Generic Core Scale Short Form.up to 2 years

Scale scores 0-100. Higher score=better Health-Related Quality of Llife

Trial Locations

Locations (25)

Hôpital Universitaire Necker-Enfants Malades

🇫🇷

Paris, France

Centre Hospitalier Universitaire (CHU) de Toulouse - Hôpital des Enfants

🇫🇷

Toulouse, France

University Hospital Freiburg - Centre for Paediatric and Adolescent Medicine

🇩🇪

Freiburg, Baden-Wurtemberg, Germany

Otto Von Guericke Universitat

🇩🇪

Magdeburg, Sachsen-Anhalt, Germany

UCSF Benioff Children's Hospital

🇺🇸

Oakland, California, United States

University of Missouri

🇺🇸

Columbia, Missouri, United States

Childrens Hospital Colorado

🇺🇸

Aurora, Colorado, United States

Children's National Hospital

🇺🇸

Washington DC, District of Columbia, United States

Johns Hopkins School of Medicine

🇺🇸

Baltimore, Maryland, United States

Vanderbilt University Medical Center

🇺🇸

Nashville, Tennessee, United States

University of Wisconsin Madison - Waisman Center Bone Dysplasia Clinic

🇺🇸

Madison, Wisconsin, United States

Murdoch Children's Research Institute

🇦🇺

Parkville, Victoria, Australia

London Health Sciences Centre - Children's Hospital of Western Ontario

🇨🇦

London, Ontario, Canada

Children's Hospital of Eastern Ontario Research Institute

🇨🇦

Ottawa, Ontario, Canada

Hôpital Femme Mère Enfant

🇫🇷

Bron, France

Université de Montréal - Centre Hospitalier Universitaire Sainte-Justine

🇨🇦

Montréal, Quebec, Canada

Haukeland University Hospital

🇳🇴

Bergen, Norway

Paediatric Clinical Research Unit at Oslo University Hospital

🇳🇴

Oslo, Norway

Hospital Pediátrico de Coimbra

🇵🇹

Coimbra, Portugal

KK Women's and Children's Hospital

🇸🇬

Singapore, Singapore

Hospital Vithas San Jose

🇪🇸

Vitoria-gasteiz, Spain

Astrid Lindgren Children's Hospital

🇸🇪

Solna, Sweden

Manchester University

🇬🇧

Manchester, United Kingdom

The Portland Hospital for Women and Children

🇬🇧

London, United Kingdom

Sheffield Children's Hospital

🇬🇧

Sheffield, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath